The price of Protalix BioTherapeutics Inc. (AMEX: PLX) closed at $1.27 in the last session, down -4.51% from day before closing price of $1.33. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 696584 shares were traded. PLX stock price reached its highest trading level at $1.3300 during the session, while it also had its lowest trading level at $1.2693.
Ratios:
We take a closer look at PLX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.12 and its Current Ratio is at 1.54. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 08, 2020, Reiterated its Buy rating but revised its target price to $11 from $3 previously.
On April 17, 2017, Rodman & Renshaw reiterated its Buy rating and also lowered its target price recommendation from $4 to $5.
On April 04, 2016, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $3.50.Rodman & Renshaw initiated its Buy rating on April 04, 2016, with a $3.50 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 19 ’23 when Bashan Dror bought 64,516 shares for $1.40 per share. The transaction valued at 90,484 led to the insider holds 132,516 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLX now has a Market Capitalization of 97.03M and an Enterprise Value of 78.75M. As of this moment, Protalix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 41.10, and their Forward P/E ratio for the next fiscal year is 1.57. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.64. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.42 while its Price-to-Book (P/B) ratio in mrq is 2.76. Its current Enterprise Value per Revenue stands at 1.20 whereas that against EBITDA is 6.09.
Stock Price History:
Over the past 52 weeks, PLX has reached a high of $3.55, while it has fallen to a 52-week low of $1.21. The 50-Day Moving Average of the stock is 1.5108, while the 200-Day Moving Average is calculated to be 1.6951.
Shares Statistics:
According to the various share statistics, PLX traded on average about 328.13K shares per day over the past 3-months and 479.51k shares per day over the past 10 days. A total of 72.95M shares are outstanding, with a floating share count of 62.74M. Insiders hold about 14.11% of the company’s shares, while institutions hold 14.05% stake in the company. Shares short for PLX as of Feb 29, 2024 were 6.44M with a Short Ratio of 19.61, compared to 5.84M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.82% and a Short% of Float of 9.06%.
Earnings Estimates
The company has 1 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.02 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.02, while EPS last year was -$0.07. The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.21 and $0.08 for the fiscal current year, implying an average EPS of $0.14. EPS for the following year is $0.81, with 1 analysts recommending between $0.81 and $0.81.
Revenue Estimates
A total of 2 analysts have provided revenue estimates for PLX’s current fiscal year. The highest revenue estimate was $74.06M, while the lowest revenue estimate was $50.2M, resulting in an average revenue estimate of $62.13M. In the same quarter a year ago, actual revenue was $65.49M, down -5.10% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $127.35M in the next fiscal year. The high estimate is $127.35M and the low estimate is $127.35M. The average revenue growth estimate for next year is up 105.00% from the average revenue estimate for this year.
